These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28990524)

  • 1. Statins and inflammation in cardiovascular disease.
    Vogiatzi G; Oikonomou E; Siasos G; Tsalamandris S; Briasoulis A; Androulakis E; Latsios G; Papaioannou S; Tsioufis K; Tousoulis D
    Curr Pharm Des; 2017 Oct; ():. PubMed ID: 28990524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins in heart failure--With preserved and reduced ejection fraction. An update.
    Tousoulis D; Oikonomou E; Siasos G; Stefanadis C
    Pharmacol Ther; 2014 Jan; 141(1):79-91. PubMed ID: 24022031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.
    Laufs U; Custodis F; Böhm M
    Drugs; 2006; 66(2):145-54. PubMed ID: 16451090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    Balakumar P; Kathuria S; Taneja G; Kalra S; Mahadevan N
    J Mol Cell Cardiol; 2012 Jan; 52(1):83-92. PubMed ID: 21968328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Werner N; Nickenig G; Laufs U
    Basic Res Cardiol; 2002 Mar; 97(2):105-16. PubMed ID: 12002257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials.
    Antonopoulos AS; Margaritis M; Lee R; Channon K; Antoniades C
    Curr Pharm Des; 2012; 18(11):1519-30. PubMed ID: 22364136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Wieland H
    Herz; 2000 Mar; 25(2):117-25. PubMed ID: 10829251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic effects of statins and related pharmacological experimental approaches.
    Alegret M; Silvestre JS
    Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
    Bjelajac A; Goo AK; Weart CW
    Ann Pharmacother; 1996 Nov; 30(11):1304-15. PubMed ID: 8913414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.
    Chłopicki S; Gryglewski RJ
    Pharmacol Rep; 2005; 57 Suppl():86-96. PubMed ID: 16415489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory and immunomodulatory effects of statins.
    Blanco-Colio LM; Tuñón J; Martín-Ventura JL; Egido J
    Kidney Int; 2003 Jan; 63(1):12-23. PubMed ID: 12472764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleiotropic effects of statins and related pharmacological experimental approaches.
    Alegret M; Silvestre JS
    Timely Top Med Cardiovasc Dis; 2007 Apr; 11():E10. PubMed ID: 17473899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rac1-mediated effects of HMG-CoA reductase inhibitors (statins) in cardiovascular disease.
    Adam O; Laufs U
    Antioxid Redox Signal; 2014 Mar; 20(8):1238-50. PubMed ID: 23919665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
    Krysiak R; Okopień B; Herman Z
    Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.
    Wierzbicki AS; Viljoen A
    Drug Saf; 2010 Feb; 33(2):115-25. PubMed ID: 20082538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease.
    Erez G; Leitersdorf E
    Eur J Vasc Endovasc Surg; 2007 Feb; 33(2):192-201. PubMed ID: 17185010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Tunnicliffe DJ; Palmer SC; Cashmore BA; Saglimbene VM; Krishnasamy R; Lambert K; Johnson DW; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007784. PubMed ID: 38018702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.